PT  - JOURNAL ARTICLE
AU  - Jurado, Aurora
AU  - Martín, María C.
AU  - Abad-Molina, Cristina
AU  - Orduña, Antonio
AU  - Martínez, Alba
AU  - Ocaña, Esther
AU  - Yarce, Oscar
AU  - Navas, Ana M.
AU  - Trujillo, Antonio
AU  - Fernández, Luis
AU  - Vergara, Esther
AU  - Rodríguez, Beatriz
AU  - Quirant, Bibiana
AU  - Martínez, Eva
AU  - Hernández, Manuel
AU  - Perurena-Prieto, Janire
AU  - Gil, Juana
AU  - Cantenys, Sergi
AU  - González-Martínez, Gema
AU  - Martínez-Saavedra, María T.
AU  - Rojo, Ricardo
AU  - Marco, Francisco M.
AU  - Mora, Sergio
AU  - Ontañón, Jesús
AU  - López-Hoyos, Marcos
AU  - Ocejo-Vinyals, Gonzalo
AU  - Melero, Josefa
AU  - Aguilar, Marta
AU  - Almeida, Delia
AU  - Medina, Silvia
AU  - Vegas, María C.
AU  - Jiménez, Yesenia
AU  - Prada, Álvaro
AU  - Monzón, David
AU  - Boix, Francisco
AU  - Cunill, Vanesa
AU  - Molina, Juan
TI  - COVID-19 in Spain: age, Interleukin-6, C Reactive Protein and lymphocytes as key clues from a multicenter retrospective study
AID  - 10.1101/2020.05.13.20101345
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.13.20101345
4099  - http://medrxiv.org/content/early/2020/05/16/2020.05.13.20101345.short
4100  - http://medrxiv.org/content/early/2020/05/16/2020.05.13.20101345.full
AB  - Background SARS-CoV-2 infection has widely spread to the hugest public health challenge to date, COVID-19 pandemic. Different fatality rates among countries are probably due to unstandardized records being carried out by local health authorities. Spanish case-fatality rate is 11.86%, far higher to those reported in Asia or by other European countries.Methods A multicenter retrospective study of demographic, clinical, laboratory and immunological features of 574 Spanish COVID-19 inpatients (59.4% males) and their outcomes was performed.Results 27.7% cases presented a mild curse, 42% a moderate one and 30.3%, severe. Ages ranged from 18 to 98 (average 63.2). Interleukin 6 was higher as increasing severity. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19 and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of renin-angiotensin system blockers was associated with moderate or mild disease courses.Conclusions Clinical course of the disease is more severe in this study than in previous literature cohorts. Age and age-related comorbidities, such as dyslipidemia, hypertension or diabetes, were also higher. Immunosenescence might be therefore a suitable explanation for immune system effectors severity-related hampering. Adaptive immunity would go exhausted and a huge ineffective and almost deleterious innate response would account for COVID-19 severity. Hypertensive patients treated with renin-angiotensin system blockers developed milder forms of the disease.Abbreviations Angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system blockers (RASB); lactate dehydrogenase (LDH); C- reactive protein (CRP); interleukin-6 (IL-6); immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polimerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); Natural Killers (NK).Article Summary main points Age arises as a crucial factor for COVID-19 severity in our series. It is as well one of the major determinants for all other COVID19 risk comorbidities, such as hypertension, diabetes or dyslipidemia. Immunosenescence would be therefore under immune overload.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred are available as an anonymized data base under requirements approbed by our ethics committee